Alnylam Pharmaceuticals Inc

Most Recent

  • uploads///SRPT
    Company & Industry Overviews

    A Look at Sarepta Therapeutics’ Stock Performance

    After its stellar rise from $54.02 on January 8 to a high of $161.51 on September 28, Sarepta stock has seen selling pressure amid the market volatility in October.

    By Kenneth Smith
  • uploads///dna _
    Company & Industry Overviews

    Why Alnylam Pharmaceuticals Stock Rose ~16% Yesterday

    Yesterday, Alnylam Pharmaceuticals (ALNY) closed the day ~16.3% higher than the previous day’s closing price.

    By Sarah Collins
  • uploads///Portfolio Breakdown of the FDGRX
    Fund Managers

    Inside the Fidelity Growth Company Fund Portfolio

    FDGRX’s core sectors are information technology, consumer discretionary, and healthcare. The first two sectors make up a little over 60% of the portfolio.

    By David Ashworth
  • uploads///Graph
    Company & Industry Overviews

    Alnylam Pharmaceuticals: Developing Therapies for Hereditary ATTR Amyloidosis

    Alnylam Pharmaceuticals (ALNY) is currently developing three investigational therapies—Patisiran, Revusiran, and ALN-TTRsc02—for the treatment of patients with hereditary ATTR amyloidosis.

    By Margaret Patrick
  • uploads///Part  Graph
    Company & Industry Overviews

    Alnylam Pharmaceuticals Initiates Phase 1 Trial of ALN-TTRsc02

    Alnylam Pharmaceuticals (ALNY) was one of the most underperforming biotech stocks for the week ended June 10, 2016. It fell 10% due to profit booking.

    By Peter Neil
  • uploads///syringe _
    Company & Industry Overviews

    Jazz Pharmaceuticals: Analysts’ View in November

    On November 12, Jazz Pharmaceuticals’ stock price closed at $148.54, which represents ~2.04% growth from the close of $145.57 on November 9.

    By Daniel Collins
  • uploads///SRPT
    Company & Industry Overviews

    Analyzing Sarepta’s Product Pipeline

    Sarepta is expected to incur R&D expenses of $277.8 million in fiscal 2018, compared with $166.71 million in fiscal 2017.

    By Kenneth Smith
  • uploads///ALNY
    Earnings Report

    What Does Alnylam Pharmaceuticals’ Valuation Trend Indicate?

    In August, of the 16 analysts covering Alnylam Pharmaceuticals, 13 have given the stock “buy” or higher ratings.

    By Kenneth Smith
  • uploads///ALNY
    Earnings Report

    What Alnylam Pharmaceuticals’ Bottom Line Trend Indicates

    Alnylam Pharmaceuticals’ interest income increased from $2.58 million in the second quarter of 2017 to $6.1 million in the second quarter of 2018.

    By Kenneth Smith
  • uploads///daniel frank  unsplash
    Company & Industry Overviews

    Why Regeneron Pharmaceuticals’ Stock Price Fell

    Of the 27 analysts tracking Regeneron Pharmaceuticals (REGN) in March, five recommended a “strong buy” and six analysts recommended a “buy.”

    By Daniel Collins
  • uploads///PROPHYLAXIS
    Company & Industry Overviews

    Sanofi Leads the Hemophilia Space on Bioverativ Acquisition

    According to Sanofi’s (SNY) 2020 roadmap, the company is focused on sustaining a position of leadership in some of its key markets, including the rare diseases space.

    By Sarah Collins
  • uploads///bioverativ_businessprofile
    Company & Industry Overviews

    Exploring Bioverativ’s Business Profile and Market Presence

    Bioverativ completed its spin-off from Biogen (BIIB) in February 2017. Bioverativ is expected to register 30% growth in 2017.

    By Sarah Collins
  • uploads///Analysts Ratings
    Company & Industry Overviews

    What Analysts Recommend for United Therapeutics in November 2017

    In November 2017, the U.S. Food and Drug Administration (or FDA) granted United Therapeutics’ (UTHR) Adcirca Pediatric exclusivity until May 21, 2018.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Givosiran May Become Major Growth Driver for Alnylam Pharmaceuticals

    On September 7, 2017, Alnylam Pharmaceuticals (ALNY) announced that it had reached an agreement with the US Food and Drug Administration (or FDA) related to the design of the phase three program for investigational RNAi therapeutic Givosiran.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Alnylam Is Preparing for Commercial Launch of Patisiran

    To ensure the smooth commercial launch of investigational RNAi therapy Patisiran, Alnylam Pharmaceuticals (ALNY) has been actively involved in building its manufacturing, quality, and distribution infrastructure in the US and Europe.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Patisiran Expected to Become Key Growth Driver for Alnylam

    Alnylam Pharmaceuticals’ (ALNY) investigational drug Patisiran is expected to target 20,000 to 30,000 patients with hereditary ATTR (or hATTR) Amyloidosis with polyneuropathy caused by amyloid deposition in nerves.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Analysts Recommend for Alnylam Pharmaceuticals and Peers

    On September 20, 2017, Alnylam Pharmaceuticals (ALNY) announced positive top-line results from phase three trial APOLLO.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Geographic Market Expansion to Boost Spinraza Sales in 2017

    In 3Q17, Biogen (BIIB) and Ionis Pharmaceuticals’ (IONS) Spinraza reported sales worth $73 million from international markets.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Alnylam Pharmaceuticals’s Therapies to Treat hATTR Amyloidosis

    The European Medicines Agency (or EMA) has approved tafamidis for stage 1 hATTR amyloidosis.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    ALNY Should Complete Revusiran’s Endeavour Trial Enrollment in Late 2016

    If the Endeavour study results in positive data, Alnylam Pharmaceuticals may become a major rare disease player like its peers United Therapeutics (UTHR) and Vertex Pharmaceuticals.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    ALNY Reports Positive Results from Patisiran’s Open Label Extension Study

    On July 1, 2016, Alnylam Pharmaceuticals (ALNY) published positive preliminary results from its ongoing Phase 2 open label extension study.

    By Margaret Patrick
  • uploads///Portfolio Breakdown of the FDGRX
    Fund Managers

    What Moves Did FDGRX Make Leading Up to 1Q16?

    FDGRX’s assets were invested across 394 holdings as of March 2016, two more than a quarter ago. It was managing assets worth $37.8 billion as of March’s end.

    By David Ashworth
  • uploads///Fidelity Growth Company Fund Vs Peers
    Company & Industry Overviews

    How Has the Fidelity Growth Company Fund Performed in 2016?

    The Fidelity Growth Company Fund (FDGRX) was among the top five largest funds in this peer group, managing assets worth $36.0 billion as of January 2016.

    By David Ashworth
  • uploads///Part  Graph
    Company & Industry Overviews

    Alnylam and ISIS Lead Mid-Cap Stocks

    Alnylam and ISIS led mid-cap stocks from August 25–31, 2015. Alnylam Pharmaceuticals (ALNY) has a weight of 1.60% in IBB and 1.15% in XBI. The stock gained 10.89% in that period.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.